Medtronic announced third-quarter financial results for its 2025 fiscal year on Tuesday. Here are three things to know: 

Our momentum continues   
We delivered mid-single-digit revenue growth for the ninth consecutive quarter, helped by strong performances across our Cardiac Ablation Solutions, Pacing, Neuromodulation, and Diabetes businesses. Innovations like our pulsed field ablation products and closed-loop sensing technologies are driving rapid growth. This is translating into strong earnings power, with significant improvement in both our gross margin and operating margin. 

Technology for the future 

We have big growth opportunities ahead. Our Symplicity™ therapy for treating uncontrolled high blood pressure reached a milestone last month when the U.S. Centers for Medicare and Medicaid Services (CMS) opened a national coverage analysis. We’ve submitted our Simplera Sync™ continuous glucose monitor for U.S. Food and Drug Administration approval, and we’re continuing to prioritize and invest in promising innovations. 

Steady guidance 
We reiterated our revenue and earnings per share (EPS) guidance for the full fiscal year 2025.  

L009-02172025

Related content

Five healthcare tech trends for 2025

Medical insertable heart monitor outperforms consumer wearable in study

Go inside the one-of-a-kind Visible Heart Lab